$Arcturus Therapeutics (ARCT.US)$
Arcturus宣布自行扩增COVID-19 mRNA疫苗候选物ARCt-154在3期研究中达到主要疗效终点
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
Arcturus宣布自行扩增COVID-19 mRNA疫苗候选物ARCt-154在3期研究中达到主要疗效终点
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
已翻译
1
$强生 (JNJ.US)$
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
$Arcturus Therapeutics (ARCT.US)$阿克图勒斯宣布批准临床试验申请,推进ARCt-154,这是针对SARS-CoV-2 Delta变种和其他引起关注的变种的下一代STARR™ mRNA-疫苗
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
已翻译
1
3
$Vir Biotechnology (VIR.US)$关于sotrovimab的初步积极结果
"COMEt-ICE试验中所有1,057名患者的主要疗效分析显示,在首个29天中,与安慰剂相比,住院时间超过24小时或死亡的风险降低了79%(调整后的相对风险减少),符合试验的主要终点"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
"COMEt-ICE试验中所有1,057名患者的主要疗效分析显示,在首个29天中,与安慰剂相比,住院时间超过24小时或死亡的风险降低了79%(调整后的相对风险减少),符合试验的主要终点"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
已翻译
2
$Arcturus Therapeutics (ARCT.US)$2021年6月2日
Primordial Genetics授予Arcturus Therapeutics一项RNA聚合酶的独家许可,用于人类和动物治疗
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
Primordial Genetics授予Arcturus Therapeutics一项RNA聚合酶的独家许可,用于人类和动物治疗
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
已翻译
$富途控股 (FUTU.US)$上个月在财报电话会议上,富途和TIGR透露他们正在申请在新加坡和美国的许可,以允许本地客户交易数字货币。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
已翻译
$向上融科 (TIGR.US)$这些公司在上个月的财报电话会议中披露,他们正在申请在新加坡和美国获得许可证,允许本地客户进行数字货币交易。
链接:https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
链接:https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
已翻译